This may occur whenever the price increase for the price payers dominates the quality increase for the fee-only patients or if the fee is set so that s < 0, which implies that fee discrimination actually lowers quality.
In the absence of fee discrimination (d = 0), we have 2 t ̃ ≥ 1 ∕ 2 due to s - v(s) ≥ 0 meaning that we always observe more price payers than fee-only patients in the market except for s = 0 where their numbers are just equal.
In the symmetric market equilibrium, both the quality s for the fee-only patients and the price p for the price-payers depend on the fee f (cf. conditions (7) and (8)).
Provided that the willingness to pay is sufficiently high, all patients then become price-payers and receive the optimal quality while there are no distortion costs so that the surplus function used by Glazer and McGuire becomes maximal.
Because of t ^ = p - s = 0, the symmetric equilibrium involves a price p = s ̄ and all patients become price-payers if Ū - s ̄ - 1 ∕ 2 ≥ 0 is satisfied, i.e., if the willingness to pay is sufficiently high. endnote g) Clearly, all patients then get the socially optimal quality.
As described above, the treatment costs of outpatient phototherapy were calculated from the societal perspective, whereas the treatment costs of home phototherapy had to be calculated using invoice prices (payers' perspective).
3. The varying degrees of market power among private insurers in the United States have led to pervasive price discrimination among payers, with prices for identical goods or services varying among payers by factors as high as 10 (see chart below).
With Reference Pricing (RP), a payer determines a maximum amount paid for a procedure, and patients selecting a provider charging more pay the difference.
Rohack said that physicians are already working under price controls, though payers don't describe their fee schedules in such terms.
However, to increase purchasing power, reduce administrative costs, and prevent unwanted price disparities across payers, cooperation on price negotiation might be justified in some cases.
They also include steps to improve transparency in classifying new drugs as innovative, linking the perceived degree of innovation of new products to reimbursed prices, and limiting payer exposure to new expensive drugs given their potential significant budget impact [ 11, 13, 17- 23].
